SWOG clinical trial number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

Open
Phase
Abbreviated Title
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Activated
05/01/2021
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Cisplatin 5-Fluorouracil Carboplatin Doxorubicin Gemcitabine hydrochloride Methotrexate Mitomycin-C Vinblastine Sulfate durvalumab

Eligibility Criteria Expand/Collapse

Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (https://www.ctsu.org) for more information and registration procedures.

Publication Information Expand/Collapse

2022

EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN/NRG Collaboration

M Joshi;S Kim;A Solanki;D Miyamoto;D Degraff;J Zou;J Meeks;T Mitin;S Collins;E Trabulsi;N Hahn;J Efstathiou;M Carducci J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster 98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)

2021

EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN & NRG Collaboration

M Joshi;S Kim;A Solanki;D Miyamoto;D Degraff;J Zou;J Meeks;T Mitin;S Collins;E Trabulsi;N Hahn;J Efstathiou;M Carducci J Clin Oncol 39, 2021 (suppl 15; abstr TPS4590) (American Society of Clinical Oncology Annual Meeting 2021, poster session)

Other Clinical Trials

SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200

S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase